GAMMA Investing LLC Has $129,000 Holdings in Vericel Corporation (NASDAQ:VCEL)

GAMMA Investing LLC raised its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 34.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,895 shares of the biotechnology company’s stock after buying an additional 748 shares during the quarter. GAMMA Investing LLC’s holdings in Vericel were worth $129,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of VCEL. GF Fund Management CO. LTD. bought a new stake in shares of Vericel during the fourth quarter valued at approximately $57,000. Smartleaf Asset Management LLC increased its position in shares of Vericel by 511.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 1,058 shares during the period. Meeder Asset Management Inc. increased its position in shares of Vericel by 8.4% during the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 183 shares during the period. Xponance Inc. bought a new stake in shares of Vericel during the fourth quarter valued at approximately $214,000. Finally, Mackenzie Financial Corp bought a new stake in shares of Vericel during the fourth quarter valued at approximately $215,000.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $41.79 on Friday. The business’s fifty day moving average price is $41.68 and its two-hundred day moving average price is $48.06. Vericel Corporation has a fifty-two week low of $37.39 and a fifty-two week high of $63.00. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of 1,393.30 and a beta of 1.32.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.14). The company had revenue of $52.60 million during the quarter, compared to the consensus estimate of $53.86 million. Vericel had a net margin of 1.25% and a return on equity of 1.09%. The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.08) earnings per share. Research analysts expect that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on VCEL shares. Wall Street Zen cut Vericel from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. Truist Financial lowered their price objective on Vericel from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. Finally, Stephens reiterated an “overweight” rating and issued a $67.00 price target on shares of Vericel in a research report on Monday, June 16th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $61.14.

Insider Activity at Vericel

In other news, CEO Dominick Colangelo sold 24,850 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the sale, the chief executive officer owned 260,354 shares in the company, valued at approximately $10,906,229.06. This represents a 8.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.20% of the company’s stock.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.